Sun Pharmaceutical and Concert Pharmaceuticals announced on Monday that they have executed an agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value.